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Abstract
Acute lymphoblastic leukemia (ALL) is the
most frequent neoplastic disease in children,
being a rare disease in adults. Many of the ad-
vances  in  pediatric  ALL  have  been  through
modifications in the doses and schedules of
available agents as opposed to the introduction
of new compounds. In recent years some im-
provements in the outcome of ALL in adults
have  occurred.  Application  of  pediatric  regi-
mens to young and middle-aged adults shows
promise to improve outcome. Advances in the
supportive  care  of  patients  undergoing  allo-
geneic  stem  cell  transplantation  (SCT),  the
use  of  alternative  sources  of  hematopoietic
stem  cells  and  the  use  of  reduced-intensity
conditioning regimens will expand the number
of patients who can benefit from this thera-
peutic  modality.  The  evaluation  of  minimal
residual disease will further stratify risk classi-
fication and redefine the role of therapeutic
modalities  such  as  SCT  or  biologic  agents.
New drugs such as thyrosin kinase inhibitors
or  monoclonal  antibodies  have  led  to  incre-
mental improvements in outcome. Advances in
the genetic and epigenetic mechanisms of the
disease provide hope that targeted therapies
can more effectively treat the disease with less
toxicity.
Introduction
Acute  lymphoblastic  leukemia  (ALL)  is  a
clonal  proliferation  of  progenitors  of  B  or  T
lymphocyte  origin  that  arise  in  the  bone
marrow. The disease has a bimodal age distri-
bution, being most commonly seen in children
with  a  subsequent  decline  in  incidence  in
middle age and a subsequent increase in older
individuals.  With  modern  chemotherapy  the
cure rate in children now exceeds 80% to 90%.
On the contrary, cure rates in adults are within
the 30-40% range, despite complete remission
(CR)  exceeding  90%  in  contemporary  treat-
ment series. However, on comparison of pa-
tients  treated  in  the  early  1980s  with  those
treated in the early 2000s, overall survival (OS)
has improved in all age groups except those
over the age of 60. The reasons for the poorer
outcome in adults are multiple, but mainly re-
late to the higher incidence of poor risk cytoge-
netic and molecular features and the decreased
ability to tolerate intensive chemotherapy regi-
mens.
Significant advances 
in the treatment of adult ALL
In recent years, new studies and new drugs
have raised the level of optimism in improving
the rate of cure in adult ALL. These advances can
be summarized as follows: a. Improvement in
the results in young adults (YA) as a result of
treatment  with  pediatric-inspired  regimens, 
b.  Improvement  in  the  outcomes  of  stem  cell
transplantation (SCT), c. Use of minimal residual
disease (MRD) assessment to stratify risk, and d.
Incorporation of new chemotherapy agents asso-
ciated with conventional chemotherapy.
Advances in the treatment 
of young adults
Several  retrospective  comparative  studies
from  the  United  States  and  Europe  have
demonstrated that survival outcomes are im-
proved in adolescent and young adults (AYA)
treated with pediatric as opposed to adult regi-
mens. The main reason for these differences
is the use of much higher doses of non-myelo-
suppressive drugs such as corticosteroids, vin-
cristine and L-asparaginase and more intense
CNS prophylaxis in AYAs treated on pediatric
regimens. Whether this improvement is also
related to other factors such as the greater ex-
perience of pediatric hematologists in caring
AYA with ALL compared with adult hematolo-
gists-oncologists  or  to  stricter  adherence  to
scheduled  treatment  regimens,  among  other
reasons, is unclear.
Several  prospective  studies  utilizing  pedi-
atric-inspired regimens in young and middle-
aged  adults  have  been  developed.  All  have
shown improvement in the outcomes, with EFS
probabilities ranging from 55% to 70%. How-
ever, in these protocols toxicity rose with in-
creasing age, the upper age limit being 40-45
years. No randomized trials comparing pedi-
atric-based protocols with standard adult pro-
tocols have been reported, but the Cancer and
Acute Leukemia Group B (CALGB 10403 pro-
tocol) is currently treating adults with Phildel-
phia chromosome- negative ALL up to the age
of 40 years with a regimen taken from one arm
of a Children’s Cancer Group (CCG) protocol.
Although this is a phase II study, the results
will be compared to the outcomes of patients
treated in the designated arm of the CCG pro-
tocol,  allowing  a  prospective  comparison.  In
addition, other important aspects such as pa-
tient and physician adherence to the dosing
and scheduling requirements of the protocol,
or psychosocial and socioeconomic issues in
AYA population will be evaluated.
Improvement in the outcomes 
of stem cell transplantation
From the results of randomized trials and
meta-analyses an evidence-based review has
been performed on the role of SCT in the treat-
ment  of  adult  ALL  recommended  allogeneic
SCT for ALL in first remission for patients with
high-risk but not standard-risk disease. How-
ever, a randomized trial from the Medical Re-
search Council (MRC) and the Eastern Coop-
erative Oncology Group (ECOG) demonstrated
significant improvement with allogeneic SCT
compared  to  the  non  pediatric-inspired
chemotherapy arm for standard-risk patients.
No  comparative  study  of  the  results  of  allo-
geneic  SCT  with  those  from  pediatric-based
regimens  currently  given  to  standard-risk
adult ALL patients is available at present.
In recent years the results of allogeneic SCT
have improved, being those from HLA-identical
siblings identical to those from well matched
unrelated donors. In addition, there is an in-
creasing  use  of  alternative  sources  of
hematopoietic progenitors, such as those from
umbilical cord blood (UCB), with the results of
unrelated  UCB  transplants  being  similar  to
those from unrelated blood in recent studies.
On  the  other  hand,  reduced-intensity  condi-
tioning (RIC) regimens in the setting of allo-
geneic SCT have been developed to reduce the
transplant-related mortality (TRM) associated
with the procedure while preserving the graft-
versus-leukemia effect. Retrospective compar-
ative studies based on registry data from either
the  European  Group  of  Blood  and  Marrow
Transplantation (EBMT) or the Center for In-
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ternational Blood and Marrow Transplant Re-
search (CIBMTR) have shown equivalent re-
sults  in  terms  of  OS  between  myeloablative
conditioning (MAC) and RIC allogeneic SCT.
The slightly greater number of relapses in the
RIC SCT was counterbalanced by the increased
TRM observed in MAC SCT. These results sug-
gest that RIC in first CR could be a suitable
therapeutic option for older adults with ALL or
for patients with comorbidity.
Minimal residual disease testing
For  more  than  one  decade  it  has  been
demonstrated that the presence of MRD at the
end of chemotherapy or at later time points in
pediatric  ALL  was  a  significant  independent
predictor of relapse, and is currently consid-
ered as the main prognostic factor in childhood
ALL, independent of baseline prognostic fac-
tors. More recent studies in adults using poly-
merase chain reaction (PCR) for immunoglob-
ulin or T-cell receptor gene rearrangements or
cytofluorometry  to  identify  aberrant  pheno-
types have also demonstrated the prognostic
value of the pattern of MRD clearance. Several
published or ongoing trials use the pattern of
MRD reduction for risk assessment and thera-
peutic decisions, i.e.: sparing those patients
with good MRD clearance from allogeneic SCT,
irrespective of their risk factors at baseline.
New chemotherapy agents
Many new drugs are being actively investi-
gated in adult ALL but a comprehensive review
of all of them is outside the scope of this ar-
ticle. One of the most important compounds is
the ABL thyrosin kinase inhibitors (TKI), such
as imatinib and the second generation TKIs,
dasatinib  and  nilotinib.  Several  trials  have
demonstrated the feasibility of their combina-
tion  with  chemotherapy  in  newly  diagnosed
patients with Ph-positive ALL, resulting in an
increase in the CR rate and allowing allogeneic
SCT to be performed in a high proportion of pa-
tients in molecular remission status. As a re-
sult of this, the survival of young and middle-
aged patients with Ph-positive ALL has signifi-
cantly improved compared with historical con-
trols.  Promising  results  have  also  been  ob-
served in elderly patients combining TKIs with
moderate intensity chemotherapy.
The second group of drugs is the monoclonal
antibodies.  CD20  is  expressed  on  B-lineage
ALL in 40% to 50% of cases with levels of ex-
pression rising to 80% to 90% in mature B ALL
or Burkitt-type leukemia or lymphoma. CD20
expression at a level ≥20% is associated with
poor prognosis especially in patients under the
age of 60 years. Recent studies have shown
that  the  inclusion  of  rituximab  into  chemo  -
therapeutic regimens has improved the prog-
nosis  of  CD20-positive  adults  with  ALL,  but
randomized trials are lacking. In addition, on
comparison with historical controls, a marked
improvement has been observed with the addi-
tion of rituximab to the specific chemotherapy
schedules in patients with Burkitt’s leukemia
or  lymphoma.  Anti-CD22  monoclonal  anti-
bodies  such  as  epratuzumab  and  others  are
being  actively  investigated  in  childhood  ALL
but results in adults are lacking. Anti CD52
(alemtuzumab)  is  under  investigation  for
eradication of MRD after induction treatment
in a phase II study from the CALGB. The bispe-
cific anti-CD19 and anti- CD3 monoclonal anti-
body blinatumomab is a promising agent that
has been investigated in a phase II study in pa-
tients in complete hematologic remission with
either persistent or recurrent MRD at any time
after initial consolidation of frontline therapy,
with very promising results. Further trials with
larger patient samples are in progress to better
understand its benefit and efficacy.
Nelarabine,  a  pro-drug  of  guanine  arabi-
noside, has shown good activity in children and
adults with relapsed or refractory T-ALL and is
currently incorporated in frontline combination
chemotherapy regimens for newly diagnosed T-
ALL. Clofarabine has been approved by the FDA
for relapsed or refractory pediatric ALL and is
now being used in combination studies with
other chemotherapy agents such as cyclophos-
phamide and etoposide with promising results
in pediatric ALL, but data are scarce in adults.
Liposomal encapsulated drugs are promising
agents to enhance the efficacy and reduce tox-
icity. Among them vincristine sulfate liposomes
injection is being investigated in combination
with dexamethasone in relapsed or refractory
ALL, with a good tolerability profile. Cytarabine
liposome has shown good activity in the treat-
ment of CNS relapse in ALL and is currently
being investigated as CNS prophylaxis with the
aim of reducing the number of intrathecal ad-
ministrations. On the contrary, liposomal an-
thracyclins do not seem to be of benefit ac-
cording to the recent results of a randomized
trial. Pegylated asparaginase led to more effec-
tive  asparagine  depletion,  but  the  dose  and
schedule remain to be defined in adults.
Other emerging therapies are under active
investigation in ALL. They include NOTCH in-
hibitors,  DNA  methylase  inhibitors,  other
BCR-ABL  inhibitors,  proteasome  inhibitors,
mammalian target of rapamycin (mTOR) in-
hibitors,  or  other  kinase  inhibitors  (MDM2,
MEK, PIM, JAK, PI3K…) among others. Many
of these compounds are the results of the mo-
lecular revolution in genomics that has pro-
vided an increasing understanding of malig-
nant diseases and this clearly holds true for
ALL. Advances in genetic and epigenetic un-
derstanding of the mechanisms of ALL provide
the hope that targeted therapies can more ef-
fectively treat the disease with less toxicity. Al-
though  the  task  ahead  is  great,  the  future
looks bright.
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